Transgene Biotek (BOM:526139) Construction In Progress: ₹0.00 Mil (As of Mar. 2026)


BOM:526139 Transgene Biotek Ltd BOM:526139
55 GF Score
Price ₹2.96
GF Value ₹6.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Construction In Progress?

Transgene Biotek BOM:526139 -2.63% 55 Construction In Progress is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:526139 with a GF Score™ of 55/100 and a GF Value™ of ₹6.55 (Possible Value Trap). The stock has 4 warning signs investors should review.

Transgene Biotek Construction In Progress Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek Construction In Progress Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:526139
55GF Score
Transgene Biotek Ltd BOM:526139
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0.00 Mil mean?
Transgene Biotek (BOM:526139) has a Construction In Progress of ₹0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Transgene Biotek and its competitors.
Is Transgene Biotek's Construction In Progress too high?
Transgene Biotek's current Construction In Progress is ₹0.00 Mil. Overall, Transgene Biotek has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's Construction In Progress compare to VRTX and REGN?
Transgene Biotek's Construction In Progress of ₹0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Transgene Biotek and its competitors. Transgene Biotek's current Construction In Progress is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.55, compared to a current price of ₹2.96 — trading 54.8% below its estimated fair value. The current Construction In Progress is ₹0.00 Mil. Transgene Biotek's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current Construction In Progress is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.96 is trading 54.8% below its estimated GF Value™ of ₹6.55. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Construction In Progress: ₹0.00 Mil
  • GF Value™: ₹6.55 vs. price of ₹2.96 (54.8% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
55GF Score

Get the complete analysis for BOM:526139

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.96
Price
₹6.55
GF Value